Journal of nuclear medicine : official publication, Society of Nuclear Medicine最新文献

{"title":"Biomarkers in Prostate Cancer: What's in the Blood?","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":"66 10","pages":"6A"},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas.","authors":"Ricarda Ebner, Jana Braach, Johannes Rübenthaler, Clemens C Cyran, Gabriel T Sheikh, Mattias Brendel, Nathalie L Albert, Reinhold Tiling, Tobias Greve, Anna Hinterberger, Matthias P Fabritius, Nicola Fink, Jens Ricke, Rudolf A Werner, Freba Grawe","doi":"10.2967/jnumed.125.270115","DOIUrl":"10.2967/jnumed.125.270115","url":null,"abstract":"<p><p>The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. <b>Methods:</b> We conducted a retrospective analysis of 8,077 SSTR imaging studies recorded in our institutional database between 2006 and 2021. In total, 223 SSTR PET/CT scans were performed for suspected meningioma, and 240 lesions were matched with histopathology results within 4 mo. Reports from SSTR PET/CT scans and histopathology were retrospectively reviewed to assess the presence of intracranial meningiomas. The positive and negative predictive values, sensitivity, specificity, and overall diagnostic accuracy of SSTR PET/CT were calculated. The SUV_max, SUV_mean, and SUV_peak were determined for each lesion. <b>Results:</b> In 222 (92.5%) of 240 lesions, meningioma was accurately identified by SSTR PET/CT and confirmed by histopathology. In 7 cases (2.9%), SSTR PET/CT suspected meningioma was not confirmed by histopathology (false-positive). Furthermore, in 11 cases (5%), meningioma was neither suspected by SSTR PET/CT nor confirmed by histopathology (true-negative result). There were no false-negative findings in our cohort. SSTR PET/CT demonstrated a sensitivity of 100% (95% CI, 98.4%-100%) and a specificity of 61.1% (95% CI, 35.8%-82.7%) in detecting meningiomas. Positive predictive value was 96.9% (95% CI, 93.8%-98.8%), and negative predictive value was 100% (95% CI, 71.5%-100%). The overall diagnostic accuracy was 97.1%. The receiver-operating-characteristic analysis for SUV_max in predicting histopathology results showed an area under the curve of 94%, indicating an excellent ability of SUV_max to distinguish between positive and negative histopathologic findings. <b>Conclusion:</b> SSTR PET/CT is a precise imaging modality for detecting intracranial meningiomas, as demonstrated by its high sensitivity. However, in 2.9% of cases, despite a positive PET/CT result, histopathology did not confirm the presence of a meningioma. Integration of MRI, histopathology, and SSTR PET/CT supports informed treatment decisions.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1561-1567"},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of ¹⁷⁷Lu-Based Radiopharmaceuticals.","authors":"Carlos Uribe, Amir Iravani, Bital Savir-Baruch, Heather Jacene, Stephen A Graves, Yuni K Dewaraja, Courtney Lawhn Heath, Thomas A Hope","doi":"10.2967/jnumed.125.270979","DOIUrl":"10.2967/jnumed.125.270979","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1528-1537"},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making Green Nuclear Medicine and Radiotheranostics Real in a Developing Country.","authors":"Sandra P Maldonado, Carlos M Pedraza, Paula A Forero, Maria M Yepes, Rafael Gómez","doi":"10.2967/jnumed.125.270499","DOIUrl":"10.2967/jnumed.125.270499","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":"1668-1669"},"PeriodicalIF":9.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁷⁷Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Boris Hadaschik, Silke Gillessen, Oliver Sartor","doi":"10.2967/jnumed.125.270836","DOIUrl":"https://doi.org/10.2967/jnumed.125.270836","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translating Research Amidst Transnational Quarrels: Thomas Beyer Talks with Bernd Pichler About the Paths of Translational Sciences.","authors":"Bernd Pichler, Thomas Beyer","doi":"10.2967/jnumed.125.271168","DOIUrl":"https://doi.org/10.2967/jnumed.125.271168","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145152250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The \"Two-Step Boost\" for [¹⁷⁷Lu]Lu-PP-F11N Therapy: Optimization of Tumor Uptake by Premedication.","authors":"Christof Rottenburger, Martin T Freitag, M Aymen Omrane, Michael Hentschel, Martin Behe, Michal Grzmil, Philipp T Meyer, Damian Wild","doi":"10.2967/jnumed.125.270588","DOIUrl":"https://doi.org/10.2967/jnumed.125.270588","url":null,"abstract":"","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Powered Quantification of Flortaucipir PET for Detecting Tau Pathology.","authors":"Hye Bin Yoo, Seung Kwan Kang, Seong A Shin, Daewoon Kim, Hongyoon Choi, Yu Kyeong Kim, Dahyun Yi, Min Soo Byun, Dong Young Lee, Jae Sung Lee","doi":"10.2967/jnumed.125.269636","DOIUrl":"https://doi.org/10.2967/jnumed.125.269636","url":null,"abstract":"<p><p>We developed and evaluated an artificial intelligence (AI)-powered approach for easier quantification of tau PET uptake without requiring structural MR to aid earlier tracking of Alzheimer disease (AD). <b>Methods:</b> We implemented a deep neural network model that normalizes ¹⁸F-AV1451 (tau) PET images to a standard template without requiring MR, using transfer learning from a model pretrained on amyloid PET. This model was integrated into an MR-free pipeline for tau PET quantification and validated on external dataset (Alzheimer Disease Neuroimaging Initiative). We examined correlations between model-derived tau uptake estimates and cognitive measures, including AD stage and episodic memory performance (<i>n</i> = 666). Longitudinal analyses were conducted to assess whether baseline tau deposition predicted future cognitive decline (<i>n</i> = 168). <b>Results:</b> The AI-powered pipeline achieved robust performance with intraclass correlation coefficients exceeding 0.97 for regional uptake estimation compared with MR-based ground truth. We also showed that the tau deposition in metatemporal regions was significantly correlated with Mini-Mental State Examination and Montreal Cognitive Assessment scores. Elevated tau PET uptake in the entorhinal cortex and inferior temporal gyrus predicted future cognitive decline. <b>Conclusion:</b> The proposed AI-powered pipeline enhances the clinical accessibility of tau PET by reducing scan costs and streamlining the uptake quantification, achieving high performance without requiring structural MR. We further demonstrated that the pipeline yields cognitively relevant outcome measures for early diagnosis and monitoring of AD progression to aid more personalized treatment strategies targeting AD biomarkers.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice.","authors":"Atefeh Hosseini, Elias Haj-Yehia, Sebastian Korste, Yalcin Kuzay, Marija Trajkovic-Arsic, Stephan Settelmeier, Miriam Cantore, Katja B Ferenz, Jens T Siveke, Ken Herrmann, Tienush Rassaf, Ulrike Hendgen-Cotta, Wolfgang A Weber, Zohreh Varasteh","doi":"10.2967/jnumed.124.268860","DOIUrl":"https://doi.org/10.2967/jnumed.124.268860","url":null,"abstract":"<p><p>Reactive fibrosis is a complex response to chronic myocardial insults, contributing to heart failure progression. Fibroblast activation protein inhibitor (FAPI) PET shows promise in distinguishing active from established fibrosis. Although antifibrotic therapies may improve left ventricular (LV) function in preclinical studies, their clinical application is limited by the lack of noninvasive imaging methods to assess fibrosis regression. This study investigates the potential of FAPI PET to track the therapeutic transition of activated fibroblast activation protein (FAP)-positive fibroblasts toward a FAP-negative phenotype. <b>Methods:</b> Mice were implanted with minipumps, infused with angiotensin-II/phenylephrine (Ang-II/PE) for 6 wk and scanned with ⁶⁸Ga-FAPI-46 PET/CT longitudinally. Control mice received saline. ⁶⁸Ga-FAPI-46 biodistribution studies were conducted at preselected time points, and FAPI uptake in the major organs was measured ex vivo. To assess the potential reversibility of the FAPI PET signal in the myocardium and liver, Ang-II/PE infusion was discontinued in a group of animals at 1 and 2 wk, respectively. LV structural and functional changes were assessed via echocardiography, tissue fibrosis via histology, and FAP expression via immunohistochemistry. <b>Results:</b> Significant ⁶⁸Ga-FAPI-46 uptake in the myocardium of treated mice peaked at 1 wk. An increase of ⁶⁸Ga-FAPI-46 uptake was also observed in the liver, peaking at 2 wk, and decreased significantly at 4 wk. The PET signal declined to an indiscernible level in the heart and liver early after Ang-II/PE withdrawal. Three weeks after the removal of the minipumps, the hearts of mice previously exposed to Ang-II/PE for 1 wk exhibited a significant reduction in fibrosis compared with mice that were sacrificed immediately after 1 wk of Ang-II/PE infusion, without the 3-wk recovery period. Coinjection with excess unlabeled FAPI-46 reduced uptake in the heart, liver, and kidneys. Despite an increase in LV wall thickness at 1 wk, the ejection fraction remained stable initially but dropped significantly by 4 wk. <b>Conclusion:</b> The rapid decline in PET signal after Ang-II/PE withdrawal shows that FAPI PET effectively visualizes dynamic changes in FAP expression, making it a valuable tool for quickly assessing treatment responses targeting activated fibroblasts. The cardiac FAPI signal precedes functional myocardial changes, indicating that FAPI PET could detect early fibrosis in cardiac remodeling leading to heart failure. FAPI PET may also visualize cardiac cirrhosis, a serious complication of cardiac disorders.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Value of Comprehensive Analysis of Metastatic Prostate Tumor Changes from First to Last [¹⁷⁷Lu]Lu-PSMA Therapy Injections Through Serial High-Speed Whole-Body 360° Cadmium-Zinc-Telluride SPECT.","authors":"Julien Kunsch, Timothée Zaragori, Pierre Olivier, Marine Claudin, Pierre-Yves Marie, Perrine Raymond, Sébastien Heyer, Antoine Verger, Laetitia Imbert, Caroline Boursier","doi":"10.2967/jnumed.125.270358","DOIUrl":"https://doi.org/10.2967/jnumed.125.270358","url":null,"abstract":"<p><p>Anger SPECT monitoring of [¹⁷⁷Lu]Lu-prostate-specific membrane antigen (PSMA) therapy provides significant prognostic information about patients with metastatic castration-resistant prostate cancer (mCRPC) but with 36- to 90-min recording times and partial body coverage. This study assesses the prognostic information from a comprehensive analysis of tumor changes from the first to the last [¹⁷⁷Lu]Lu-PSMA therapy injections, as provided by whole-body [¹⁷⁷Lu]Lu SPECT recordings from a high-speed 360° cadmium-zinc-telluride (CZT) camera of mCRPC patients. <b>Methods:</b> We included mCRPC patients treated by [¹⁷⁷Lu]Lu-PSMA-617 injections who underwent [⁶⁸Ga]Ga-PSMA-11 PET before treatment, whole-body 360° [¹⁷⁷Lu]Lu CZT SPECT recordings of only 18 min obtained 24 h after each [¹⁷⁷Lu]Lu-PSMA therapy injection, and plasma prostate-specific antigen (PSA) measurements before each injection. We used Cox proportional hazards models to predict overall survival (OS) according to PSA evolution during treatment, as well as tumor SUV_max, SUV_mean, total uptake volume, and total lesion activity (TLA; total uptake volume × SUV_mean) extracted from [⁶⁸Ga]Ga-PSMA-11 PET and the first and last [¹⁷⁷Lu]Lu SPECT scans. <b>Results:</b> We included 72 patients with a median age of 71 y (interquartile range, 64-77 y), treated with up to 6 [¹⁷⁷Lu]Lu-PSMA injections. Among 57 patients with at least 2 [¹⁷⁷Lu]Lu-PSMA treatment cycles, 35 (61%) died during a follow-up of 12.0 mo (range, 4.9-17.5 mo) from the last [¹⁷⁷Lu]Lu-PSMA injection. Most PSA, PET, and SPECT variables were significant univariate predictors of OS. However, only 2 [¹⁷⁷Lu]Lu SPECT variables were selected as multivariate predictors: SPECT detection of new bone lesions during treatment (<i>P</i> < 0.0001) and final SPECT TLA (<i>P</i> = 0.0007). Means of survival times were 19.7 mo (95% CI, 16.6-22.8 mo) in the 19 patients who showed no new bone lesions and final TLA lower than the median of 750 mL·SUV, 14.4 mo (95% CI, 10.9-18.0 mo) in the 19 patients with only 1 of these 2 criteria, and 6.9 mo (95% CI, 4.5-9.6 mo) in the 19 patients with neither criterion. <b>Conclusion:</b> A comprehensive analysis of tumor changes from the first to the last [¹⁷⁷Lu]Lu-PSMA injections, obtained with fast whole-body 360° [¹⁷⁷Lu]Lu CZT SPECT recordings, provides strong prognostic information about mCRPC patients, outperforming conventional OS predictors such as PSA evolution and [⁶⁸Ga]Ga-PSMA-11 PET variables before treatment.</p>","PeriodicalId":94099,"journal":{"name":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}